Vivos Therapeutics, Inc. (VVOS)

NCM – Цена в реальном времени. Валюта: USD

0.45

+0.01 (3.13%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.45

-0.00 (-0.13%)

После закрытия: Jun 26, 2026, 6:39 PM EDT

11.06.2026

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it intends to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering pursuant to which the Company would distribute, as a dividend, transferable subscription rights to its shareholders.

10.06.2026

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

08.06.2026

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.

05.06.2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

21.05.2026

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

20.05.2026

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Year-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today reported financial results and operating highlights for the first quarter ended March 31, 2026.

09.05.2026

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.

Видео

No Data

There is no data to display

Пресс-релизы

11.06.2026

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

10.06.2026

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

08.06.2026

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

05.06.2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Search stocks

Vivos Therapeutics, Inc. (VVOS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing